文献

PA007275.r1: Syd Labs体内实验级重组抗小鼠CD137 (TNFRSF9 or 4-1BB)单克隆抗体(克隆号LOB12.3) ，大鼠IgG1 Kappa

LOB12.3 抗体可结合 4-1BB（TNFRSF9 或 CD137），后者是肿瘤坏死因子受体（TNF受体）家族中具有代表性的共刺激受体。4-1BB 蛋白在多种细胞类型中表达，包括活化的 T 细胞、NK 细胞、树突状细胞（DC）、B 细胞、单核细胞和中性粒细胞。抗 4-1BB 诱导的 CD8+ T 细胞应答在抗肿瘤免疫中发挥主导作用，具体表现为诱导 CD8+ T 细胞释放更多效应分子、促进 CD8+ T 细胞增殖并减少其凋亡。

抗小鼠 CD137 (4-1BB) 单克隆抗体（克隆号：LOB12.3）参考文献：

1. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.

Qi, et al. Nat Commun. 2019 May 17;10(1):2141. PMID: 31101822

“The co-stimulatory receptor 4-1BB (CD137) is a major target for cancer immunotherapy due to its ability to enhance T cell-mediated anti-tumor responses. … Here, we demonstrate that optimizing the balance between agonistic strength and FcγR binding affinity is critical to maximizing therapeutic efficacy. … These findings suggest a design strategy for developing safer and more effective anti-4-1BB antibodies with minimized systemic toxicities.”

2. Intratumoral activation of 41BB co-stimulatory signals enhances CD8 T cell expansion and modulates tumor-infiltrating myeloid cells.

An, et al. J Immunother Cancer. 2020 Dec;8(2):e001384. PMID: 33328224

“Intratumoral delivery of 4-1BB (CD137) agonistic antibodies is an attractive approach to restrict immune activation to the tumor microenvironment. … This study shows that localized CD137 activation significantly drives CD8+ T cell expansion and rewires the landscape of tumor-infiltrating myeloid cells. … Consequently, targeting 4-1BB locally represents a highly viable therapeutic avenue to overcome systemic immune-related adverse events.”

3. TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.

Takuya, et al. Cell Rep. 2023 Nov 28;42(11):113354. PMID: 37924248

“CD137 (4-1BB) is typically considered a co-stimulatory molecule that acts in concert with T-cell receptor (TCR) activation. … We demonstrate that TCR-independent CD137 signaling can directly drive the proliferation and terminal differentiation of exhausted CD8+ T cells in chronic viral or tumor settings. … These results reveal a novel role for CD137 agonists in reviving exhausted T-cell populations independently of antigen recognition.”

4. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

Hoves, et al. Clin Cancer Res. 2020 May 15;26(10):2310-2321. PMID: 32156742

“Agonistic antibodies targeting CD137 (4-1BB) have shown powerful antitumor effects in preclinical models, but clinical development has been hindered by severe liver toxicity. … Here, we present a differentiated agonistic antibody that achieves robust antitumor efficacy and eradicates large established tumors. … Crucially, this therapeutic approach avoids systemic hepatotoxicity, establishing a wider therapeutic window for clinical applications.”

5. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.

Yuan, et al. Nat Commun. 2017 Dec 22;8(1):2248. PMID: 29273763

“Systemic administration of immunostimulatory monoclonal antibodies, such as those targeting 4-1BB, frequently induces severe off-target inflammatory toxicities. … To address this, we developed a nanoparticle-anchoring platform that selectively delivers CD137 agonists to the tumor tissue. … This localized retention leads to potent anti-cancer immunity without generating systemic toxicities, demonstrating a safer method for administering immune checkpoint agonists.”

了解更多抗小鼠CD137 (TNFRSF9 or 4-1BB)单克隆抗体（clone：LOB12.3）引用文献，请查看：抗小鼠CD137抗体（克隆号LOB12.3）引用文献

Syd Labs抗小鼠CD137(TNFRSF9 or 4-1BB)重组抗体（克隆号LOB12.3），大鼠IgG1 Kappa（货号：PA007275.r1）推荐同型对照抗体:

重组大鼠IgG1同型对照抗体，体内实验级（In vivo Grade Recombinant Rat IgG1 Isotype Control Antibody）